Zbigniew K. Wszolek is a distinguished neurologist and neuroscientist at Mayo Clinic Florida, renowned for his work in characterizing familial neurodegenerative disorders. His clinical and genetic research has been pivotal in identifying the genetic basis of numerous movement disorders and dementias.
Zbigniew K. Wszolek is a distinguished neurologist and neuroscientist at Mayo Clinic Florida, renowned for his work in characterizing familial neurodegenerative disorders. His clinical and genetic research has been pivotal in identifying the genetic basis of numerous movement disorders and dementias.
Key Discoveries
PARK2 (Parkin) and PARK6 (PINK1)
Wszolek's group played a crucial role in identifying mutations in [PARK2](/genes/parkin) (parkin) and [PARK6](/genes/pink1) (PINK1) as causes of early-onset familial Parkinson's disease. These discoveries established that mitochondrial dysfunction is a key pathogenic mechanism in PD.
LRRK2 Characterization
Wszolek has been instrumental in characterizing the phenotypic spectrum of [LRRK2](/genes/lrrk2) mutations, including the identification of the original LRRK2 G2019S founder mutation in families from Southern Europe and North Africa. His work has defined:
The clinical presentation of LRRK2-associated PD
Penetrance estimates and age of onset ranges
Response to dopaminergic therapies
Phenotypic variability within and between families
Tauopathies and FTD
His research also encompasses frontotemporal dementia and related tauopathies, contributing to understanding the clinical and genetic heterogeneity of these conditions.
Clinical characterization of familial neurodegenerative disorders
Genetic linkage analysis and mutation screening
Genotype-phenotype correlation studies
Large family studies and founder mutation identification
Research Themes
Familial Parkinson's Disease Genetics
Wszolek's laboratory has been at the forefront of identifying genes responsible for familial forms of Parkinson's disease. His work has established:
PARK2 (Parkin): Autosomal recessive early-onset PD — first identified as a cause of juvenile-onset parkinsonism
PARK6 (PINK1): Autosomal recessive early-onset PD — established role of mitochondrial dysfunction
LRRK2: Autosomal dominant PD — most common genetic cause of late-onset familial PD
Phenotype-Genotype Correlations
A major focus has been understanding how different genetic mutations lead to different clinical phenotypes:
Age of onset patterns (juvenile vs. early-onset vs. late-onset)
Motor phenotype variations (tremor-dominant vs. PIGD)
Non-motor features (dementia, autonomic dysfunction)
Response to treatment and disease progression
Founder Mutations and Population Genetics
Wszolek has studied founder mutations in various populations:
LRRK2 G2019S in Southern European and North African families
Parkin mutations in various populations
PINK1 mutations in early-onset families
This work has implications for genetic testing, counseling, and understanding disease pathogenesis.
Recent Publications
2021
[Ataxia and spasticity as presenting features of parkinsonism](https://pubmed.ncbi.nlm.nih.gov/33731421/). Neurology, 2021
2020
[LRRK2-associated Parkinson's disease: clinical phenotype](https://pubmed.ncbi.nlm.nih.gov/32078116/). Movement Disorders, 2020
2018
[Parkin mutations and Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/30559380/). Lancet Neurology, 2018
2005
[LRRK2 G2019S mutation in familial Parkinson's disease](https://doi.org/10.1056/NEJMoa051500). NEJM, 2005
[PINK1 mutations in early-onset familial Parkinson's disease](https://doi.org/10.1056/NEJMoa044826). NEJM, 2005
Institutional Context
Primary institutional affiliation:
[Mayo Clinic Florida](/institutions/mayo-clinic) — USA
Mayo Clinic Florida provides an ideal environment for Wszolek's work, with access to large patient cohorts and state-of-the-art genetic and neuropathological resources.